Publications by authors named "F Eyvrard"
Introduction: In response to the COVID-19 pandemic, France was under lockdown for the first time from March 17 to May 10, 2020.
Purpose Of The Research: The aim of this work is to study the impact of lockdown on outpatients’ visits to the hospital pharmacy to collect chronic medication, in order to highlight the pharmaceutical classes concerned and to assess whether a decrease in medication adherence could be observed.
Method: Retrospectively, using hospital dispensing traceability software, the dispensing of drugs during the eight weeks of lockdown was compared with that during the two eight-week periods before and after lockdown.
Article Synopsis
- In France, mental health institutions' funding is allocated annually, and Esketamine is used for treating resistant major depressive disorder since its approval in 2019.
- The study assessed if income from treating patients with Esketamine could cover its high purchase costs; seven patients used 714 devices costing €142,800, while the institution earned €149,054 in revenue.
- The analysis showed that 95.8% of the income was consumed by Esketamine expenses, raising concerns about drug pricing and highlighting inadequate funding for expensive psychiatric treatments.
Objectives: Highly active antiretroviral therapies against the human immunodeficiency virus are available for patients in France in community pharmacy or in hospital pharmacy. More than 20 years after the implementation of the dual delivery system, it seems necessary to question the relevance of the dual dispensing circuit both in terms of service provided to patients and expenditure for health insurance.
Methods: The health insurance files were used to quantify the delivery of antiretrovirals therapies in the community pharmacy and in the hospital pharmacy.
Background: Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19.
View Article and Find Full Text PDF